211 related articles for article (PubMed ID: 37519024)
1. Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients.
Chen M; Zeng Z; Li X; Qin W; Cai X; Chen S; Lu X
Int J Lab Hematol; 2023 Dec; 45(6):899-907. PubMed ID: 37519024
[TBL] [Abstract][Full Text] [Related]
2. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
3. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.
Wakita S; Marumo A; Morita K; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Nakayama K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Tashiro H; Sakaguchi M; Yui S; Arai K; Kitano T; Miyata M; Arai H; Kanda M; Itabashi K; Fukuda T; Kanda Y; Yamaguchi H
Cancer Sci; 2023 Apr; 114(4):1297-1308. PubMed ID: 36610002
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients.
Elrhman HAEA; El-Meligui YM; Elalawi SM
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e960-e969. PubMed ID: 34376373
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients.
Moualla Y; Moassass F; Al-Halbi B; Al-Achkar W; Georgeos M; Yazigi H; Khamis A
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1387-1395. PubMed ID: 35485701
[TBL] [Abstract][Full Text] [Related]
7. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.
Loghavi S; Zuo Z; Ravandi F; Kantarjian HM; Bueso-Ramos C; Zhang L; Singh RR; Patel KP; Medeiros LJ; Stingo F; Routbort M; Cortes J; Luthra R; Khoury JD
J Hematol Oncol; 2014 Oct; 7():74. PubMed ID: 25281355
[TBL] [Abstract][Full Text] [Related]
9. FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.
Tang S; Shen H; Mao X; Dai H; Zhu X; Xue S; Ding Z; Lu J; Wu D; Tang X
Int J Hematol; 2017 Oct; 106(4):552-561. PubMed ID: 28616699
[TBL] [Abstract][Full Text] [Related]
10. [Effect of FLT3-ITD with DNMT3A R882 double-mutation on the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Tang SH; Lu Y; Zhang PS; Liu XH; Du XH; Chen D; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Pei RZ; Tang XW
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):552-557. PubMed ID: 30122013
[No Abstract] [Full Text] [Related]
11. The effect of haploidentical hematopoietic stem cell transplantation on comutations based on next-generation sequencing in adult acute myeloid leukemia patients with the FLT3-ITD mutation.
Tang F; Zhao X; Ruan G; Jiang Q; Jiang H; Xu L; Wang Y; Zhang X; Liu K; Huang X
Hematol Oncol; 2023 Oct; 41(4):733-742. PubMed ID: 37272204
[TBL] [Abstract][Full Text] [Related]
12. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
[TBL] [Abstract][Full Text] [Related]
13. [Clinical Value of Translocator Protein Gene in Evaluating the Efficacy of
Tang SH; Lu Y; Zhang PS; Chen D; Liu XH; DU XH; Cao JJ; Li SY; Sha KY; Chen LG; Zhuang XX; Ye PP; Lin L; Pei RZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):45-49. PubMed ID: 36765475
[TBL] [Abstract][Full Text] [Related]
14. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
[TBL] [Abstract][Full Text] [Related]
15. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
Guryanova OA; Shank K; Spitzer B; Luciani L; Koche RP; Garrett-Bakelman FE; Ganzel C; Durham BH; Mohanty A; Hoermann G; Rivera SA; Chramiec AG; Pronier E; Bastian L; Keller MD; Tovbin D; Loizou E; Weinstein AR; Gonzalez AR; Lieu YK; Rowe JM; Pastore F; McKenney AS; Krivtsov AV; Sperr WR; Cross JR; Mason CE; Tallman MS; Arcila ME; Abdel-Wahab O; Armstrong SA; Kubicek S; Staber PB; Gönen M; Paietta EM; Melnick AM; Nimer SD; Mukherjee S; Levine RL
Nat Med; 2016 Dec; 22(12):1488-1495. PubMed ID: 27841873
[TBL] [Abstract][Full Text] [Related]
16. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
[TBL] [Abstract][Full Text] [Related]
17. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of
Tan M; Ng IKS; Chen Z; Ban K; Ng C; Chiu L; Seah E; Lin M; Tai BC; Yan B; Ng CH; Chng WJ
J Clin Pathol; 2017 Aug; 70(8):669-676. PubMed ID: 28100593
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
20. DNMT3A mutations in Chinese childhood acute myeloid leukemia.
Li W; Cui L; Gao C; Liu S; Zhao X; Zhang R; Zheng H; Wu M; Li Z
Medicine (Baltimore); 2017 Aug; 96(31):e7620. PubMed ID: 28767575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
